RU2482870C1 - Agent inducing hemopoietic stem cell differentiation into thrombocytes - Google Patents
Agent inducing hemopoietic stem cell differentiation into thrombocytes Download PDFInfo
- Publication number
- RU2482870C1 RU2482870C1 RU2012106870/15A RU2012106870A RU2482870C1 RU 2482870 C1 RU2482870 C1 RU 2482870C1 RU 2012106870/15 A RU2012106870/15 A RU 2012106870/15A RU 2012106870 A RU2012106870 A RU 2012106870A RU 2482870 C1 RU2482870 C1 RU 2482870C1
- Authority
- RU
- Russia
- Prior art keywords
- thrombocytes
- stem cell
- cell differentiation
- cells
- agent inducing
- Prior art date
Links
- 210000001772 blood platelet Anatomy 0.000 title abstract description 13
- 230000024245 cell differentiation Effects 0.000 title abstract description 3
- 230000001939 inductive effect Effects 0.000 title abstract description 3
- 210000003995 blood forming stem cell Anatomy 0.000 title 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 4
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 claims abstract description 3
- 230000004069 differentiation Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 6
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 6
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 6
- 102100032999 Integrin beta-3 Human genes 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108010072220 Cyclophilin A Proteins 0.000 description 3
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 238000011127 radiochemotherapy Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KMPLYESDOZJASB-PAHRJMAXSA-N (6s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-hydroxy-6-methoxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one;(z)-n-carbamoyl-2-ethylbut-2-enamide;6-ethoxy-1,3-benzothiazole-2-sulfonamide Chemical compound CC\C(=C\C)C(=O)NC(N)=O.CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](OC)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 KMPLYESDOZJASB-PAHRJMAXSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940124569 cytoprotecting agent Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011546 protein dye Substances 0.000 description 1
- 101150067463 rfcS gene Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Изобретение относится к области медицины.The invention relates to the field of medicine.
Применение химиотерапии у онкологических больных приводит к повреждению и гибели кроветворных клеток костного мозга со снижением количества тромбоцитов в периферической крови. Тромбоцитопения является серьезной проблемой в лечении онкологических больных (Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau' F, Scambia G. // Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann. Oncology. 2003 Jul; 14(7): 1086-93).The use of chemotherapy in cancer patients leads to damage and death of hematopoietic cells of the bone marrow with a decrease in the number of platelets in the peripheral blood. Thrombocytopenia is a serious problem in the treatment of cancer patients (Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau 'F, Scambia G. // Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann. Oncology. 2003 Jul; 14 (7): 1086-93).
Известно ограниченное количество средств, способствующих дифференцировке тромбоцитов. Наиболее близким к заявляемому средству является тромбопоэтин (прототип). Тромбопоэтин - гормон, индуцирующий дифференцировку мегакариоцитарного ростка из стволовых клеток костного мозга и влияющий на пролиферацию, созревание и дифференцировку мегакариоцитов и образование тромбоцитов (Nagahisa H, Nagata Y, Ohnuki T, Osada M, Nagasawa Т, Abe T, Todokoro K. // Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation. Blood. 1996 Feb 15; 87(4):1309-16).A limited number of agents are known to promote platelet differentiation. Closest to the claimed agent is thrombopoietin (prototype). Thrombopoietin is a hormone that induces the differentiation of a megakaryocytic germ from bone marrow stem cells and affects the proliferation, maturation and differentiation of megakaryocytes and platelet formation (Nagahisa H, Nagata Y, Ohnuki T, Osada M, Nagasawa T, Abe T, Todokoro K. // Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation. Blood. 1996 Feb 15; 87 (4): 1309-16).
Задачей изобретения является расширение ассортимента средств, индуцирующих дифференцировку тромбоцитов. Задача решается тем, что предлагается новое средство, индуцирующее дифференцировку тромбоцитов, представляющее собой рекомбинантный циклофилин А человека (рчЦфА).The objective of the invention is to expand the range of agents that induce platelet differentiation. The problem is solved by the fact that a new tool is proposed that induces platelet differentiation, which is a recombinant human cyclophilin A (rhtsfA).
РчЦфА известен как белок с молекулярной массой 18 кД, присутствующий в различных тканях, усиливает миграцию стволовых клеток, предшественников дендритных клеток, гранулоцитов и лимфоцитов из костного мозга на периферию, способствует дифференцировке дендритных клеток и гранулоцитов (Khromykh L.M., Kulikova N.L., Anfalova T.V. et al. // Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell Immunol. - 2007. - vol. 249(1). - p.46-53; Bharadwaj U, Zhang R, Yang H, Li M, Doan LX, Chen C, Yao Q. // Effects of cyclophilin A on myeloblastic cell line KG-1 derived dendritic like cells (DLC) through p38 MAP kinase activation. J Surg Res. 2005 Jul 1; 127(1):29-38; Патент РФ №2370277).RFCfA is known as a protein with a molecular weight of 18 kD, present in various tissues, enhances the migration of stem cells, precursors of dendritic cells, granulocytes and lymphocytes from bone marrow to the periphery, and promotes the differentiation of dendritic cells and granulocytes (Khromykh LM, Kulikova NL, Anfalova TV et al . // Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell Immunol. - 2007. - vol. 249 (1). - p. 46-53; Bharadwaj U, Zhang R, Yang H, Li M, Doan LX, Chen C, Yao Q. // Effects of cyclophilin A on myeloblastic cell line KG-1 derived dendritic like cells (DLC) through p38 MAP kinase activation. J Surg Res. 2005 Jul 1; 127 (1): 29- 38; RF Patent No. 2370277).
РчЦфА усиливает адгезивные свойства тромбоцитов (Патент РФ №2435607). Для выполнения поставленной задачи оценивали влияние рчЦфА на дифференцировку стволовых клеток лейкаферезного концентрата и костного мозга онкологических больных после химио-лучевой терапии и здоровых доноров. Дифференцировку клеток тромбоцитарного ростка оценивали по экспрессии маркера CD61, который присутствует на всех этапах становления тромбоцитов от стволовых до зрелых клеток.RFCfA enhances the adhesive properties of platelets (RF Patent No. 2435607). To accomplish this task, the effect of rhcfA on the differentiation of stem cells from leukapheresis concentrate and bone marrow of cancer patients after chemo-radiation therapy and healthy donors was evaluated. Platelet cell differentiation was evaluated by expression of the marker CD61, which is present at all stages of platelet formation from stem to mature cells.
Для получения рчЦфА использовали клетки Escherichia coli BL21, трансформированные плазмидой pCyPAwt/pGEX-2TK (M.Bukrinsky Albert Einstein College of Medicine of Yeshiva University, США). Качество полученного рчЦфА оценивали с помощью SDS-PAAG по Лэммли (U.K.Laemmli. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. Nature, 1970; V.227, P.680-685). Концентрацию рчЦфА определяли по методу Бредфорда (Bradford, M.M. (1976) A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Anal. Biochem. 72:248-254). Идентификацию рчЦфА проводили с помощью Wetstern-blott анализа (Gershoni JM, Palade GE. Electroblotting of proteins from polyacrylamide gels. Methods Mol Biol. 2004; 244:345-352) с использованием кроличьих антител к рчЦфА (е-Biosciences). Чистота полученного рчЦфА составила более 98%.Escherichia coli BL21 cells transformed with the plasmid pCyPAwt / pGEX-2TK (M. Bukrinsky Albert Einstein College of Medicine of Yeshiva University, USA) were used to obtain rhcfA. The quality of the rhcfA obtained was evaluated using Laemmli SDS-PAAG (U. K. Laemmli. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. Nature, 1970; V.227, P.680-685). The concentration of rfCfA was determined by the Bradford method (Bradford, M. M. (1976) A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Anal. Biochem. 72: 248-254). The identification of rfcPA was carried out using Wetstern-blott analysis (Gershoni JM, Palade GE. Electroblotting of proteins from polyacrylamide gels. Methods Mol Biol. 2004; 244: 345-352) using rabbit antibodies to rfcA (e-Biosciences). The purity of the obtained rhcfA was more than 98%.
Для исследования использовали лейкаферезный концентрат, представляющий собой фракцию клеток периферической крови с преобладанием мононуклеаров. Лейкаферезный концентрат получали у пяти онкологических больных после химио-лучевой терапии путем сепарации клеток периферической крови.For the study, leukapheresis concentrate was used, which is a fraction of peripheral blood cells with a predominance of mononuclear cells. Leukapheresis concentrate was obtained from five cancer patients after chemo-radiation therapy by separation of peripheral blood cells.
В качестве образцов использовали костный мозг трех онкологических больных и трех здоровых доноров.The bone marrow of three cancer patients and three healthy donors were used as samples.
С целью мобилизации стволовых кроветворных клеток пациентам предварительно проводили стимуляцию кроветворения гранулоцитарным колониестимулирующим фактором (Г-КСФ) в стандартной дозе 5 мкг/кг в течение 3-14 дней. Количество CD34+ стволовых клеток в аликвотах образцов ленкаферезного концентрата варьировало от 0,25% до 1,3%, в аликвотах образцов костного мозга от 2,1% до 5,8%.In order to mobilize hematopoietic stem cells, patients were previously stimulated with hematopoiesis with granulocyte colony stimulating factor (G-CSF) in a standard dose of 5 μg / kg for 3-14 days. The number of CD34 + stem cells in aliquots of samples of lenkapheresis concentrate varied from 0.25% to 1.3%, in aliquots of bone marrow samples from 2.1% to 5.8%.
Клетки крови и костного мозга человека культивировали при концентрации 1×106/мл в питательной среде альфа-МЕМ (для клеток крови, Gibco) и IMDM (для клеток костного мозга, Gibco) с добавлением 20% эмбриональной телячьей сыворотки, 2-меркаптоэтанола 5×10-5 M, L-глютамина 2 мМ и цифрана 100 мкг/мл. Культивирование клеток проводили при температуре 37°C в присутствии 5% CO2 в пластиковых 24-луночных планшетах (Corning) в течение 5 дней. Концентрация рчЦфА составила 10,0 мкг/мл.Human blood and bone marrow cells were cultured at a concentration of 1 × 10 6 / ml in alpha-MEM (for blood cells, Gibco) and IMDM (for bone marrow, Gibco) nutrient medium supplemented with 20% fetal calf serum, 2-mercaptoethanol 5 × 10 -5 M, L-
Анализ клеточных маркеров проводили при помощи проточного цитофлюориметра Faxcanto II (Beckton Dickenson) с использованием флюоресцентномеченных антител анти-CD61Fitc (E-Bioscience). Контрольные маркеры были установлены в соответствии с изотипическим контролем: анти-IgG Fitc. Для исключения неспецифического окрашивания до окраски с флюоресцентными антителами клетки человека инкубировали с донорской сывороткой крови (IV группа) в разведении 1:10. Погибшие клетки исключали путем гейтирования в параметрах прямого и бокового рассеивания (FSC/SSC), а также включения 7-амино-актиномицина D (Calbiochem, CA). Данные анализировали при помощи программ BD FACSDiva (версия 6.1.2, Beckton Dickinson) и WinMDI 2.8 (J.Trotter, http://facs.scripps.edu/).Cell marker analysis was performed using a Faxcanto II flow cytometer (Beckton Dickenson) using fluorescently labeled anti-CD61Fitc antibodies (E-Bioscience). Control markers were set according to isotypic control: anti-IgG Fitc. To exclude nonspecific staining, before staining with fluorescent antibodies, human cells were incubated with donor blood serum (group IV) at a 1:10 dilution. Dead cells were excluded by gating in forward and side scatter parameters (FSC / SSC), as well as inclusion of 7-amino-actinomycin D (Calbiochem, CA). Data was analyzed using the BD FACSDiva (version 6.1.2, Beckton Dickinson) and WinMDI 2.8 (J.Trotter, http://facs.scripps.edu/) programs.
Изобретение иллюстрировано фиг.1 и 2.The invention is illustrated in figures 1 and 2.
На фиг.1(А-Г) представлено влияние рчЦфА на дифференцировку тромбоцитов в лейкаферезном концентрате.Figure 1 (A-D) shows the effect of rhcfA on platelet differentiation in leukapheresis concentrate.
На фиг.1 (А и Б) по оси абсцисс обозначен уровень экспрессии маркера CD34, по оси ординат (SSC) - уровень клеточной гранулярности. На фиг.1А представлена идентификация стволовых клеток, несущих маркер CD34+, в контроле, и на фиг.1Б - в присутствии рчЦфА (очерченный регион).In Fig. 1 (A and B), the level of expression of the CD34 marker is indicated on the abscissa axis, and the level of cell granularity on the ordinate axis (SSC) is indicated. On figa presents the identification of stem cells bearing the marker CD34 + , in the control, and figb - in the presence of rftsfA (outlined region).
На фиг.1(В и Г) по оси абсцисс показан уровень экспрессии маркера CD61, по оси ординат - уровень экспрессии маркера CD34. На фиг.1В представлено количество стволовых клеток, несущих маркер CD61 в контроле (24,69%), и на фиг.1Г - под влиянием рчЦфА (65,81%).Figure 1 (B and D) shows the expression level of the CD61 marker along the abscissa axis, and the expression level of the CD34 marker along the ordinate axis. Figure 1B shows the number of stem cells bearing the CD61 marker in the control (24.69%), and Figure 1G shows the effect of rhCfa (65.81%).
На фиг.2 (А-Г) показано влияние рчЦфА на дифференцировку тромбоцитов в костном мозге.Figure 2 (A-D) shows the effect of rhcfA on platelet differentiation in the bone marrow.
На фиг.2 (А и Б) по оси абсцисс обозначен уровень экспрессии маркера CD34, по оси ординат - уровень клеточной гранулярности (SSC).In Fig. 2 (A and B), the level of expression of the CD34 marker is indicated on the abscissa axis, and the level of cell granularity (SSC) on the ordinate axis.
На фиг.2А представлена идентификация стволовых клеток костного мозга в контроле и на фиг.2Б - в присутствии рчЦфА (очерченный регион).On figa presents the identification of stem cells of the bone marrow in the control and figb - in the presence of rftsfA (outlined region).
На фиг.2 (В и Г) по оси абсцисс показан уровень экспрессии маркера CD61, по оси ординат - уровень экспрессии маркера CD34.Figure 2 (B and D) shows the expression level of the CD61 marker along the abscissa axis, and the expression level of the CD34 marker along the ordinate axis.
На фиг.2 В представлено количество стволовых клеток, несущих маркер CD61 в контроле (1,11%) и на фиг.2Г - под влиянием рчЦфА (3,83%).Figure 2B shows the number of stem cells bearing the CD61 marker in the control (1.11%), and Figure 2G shows the effect of rhCfa (3.83%).
Таким образом, показано, что под влиянием рчЦфа наблюдается увеличение количества стволовых клеток, экспрессирующих маркер CD61, в лейкаферезном концентрате и костном мозге - в 3 раза относительно контрольных значений.Thus, it was shown that, under the influence of rccf, there is an increase in the number of stem cells expressing the CD61 marker in leukapheresis concentrate and bone marrow - 3 times relative to control values.
Технический результат изобретенияThe technical result of the invention
Средство, индуцирующее дифференцировку тромбоцитов, представляет собой рекомбинантный циклофилин А человека.The platelet differentiation inducing agent is human recombinant cyclophilin A.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012106870/15A RU2482870C1 (en) | 2012-02-27 | 2012-02-27 | Agent inducing hemopoietic stem cell differentiation into thrombocytes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012106870/15A RU2482870C1 (en) | 2012-02-27 | 2012-02-27 | Agent inducing hemopoietic stem cell differentiation into thrombocytes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2482870C1 true RU2482870C1 (en) | 2013-05-27 |
Family
ID=48791819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012106870/15A RU2482870C1 (en) | 2012-02-27 | 2012-02-27 | Agent inducing hemopoietic stem cell differentiation into thrombocytes |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2482870C1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2606764C2 (en) * | 2011-05-13 | 2017-01-10 | Университет Токио | Method for producing polyploidized megakaryocyte and platelets |
| RU2756000C2 (en) * | 2015-09-15 | 2021-09-24 | Мегакарион Корпорейшн | Method for the production of platelets by a method for rotational mixing of the culture |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990012108A1 (en) * | 1989-04-03 | 1990-10-18 | Genetics Institute, Inc. | Megakaryocyte growth promoting activity |
| WO2007058497A1 (en) * | 2005-11-17 | 2007-05-24 | Ewha University - Industry Collaboration Foundation | Method for inducing the differentiation of human myelogenous leukemia cells into megakaryocytes or thrombocytes |
| US20090226406A1 (en) * | 2002-04-12 | 2009-09-10 | Hariri Robert J | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| RU2370277C1 (en) * | 2008-04-21 | 2009-10-20 | Государственное учреждение Российский онкологический научный центр им Н.Н. Блохина РАМН | Cyclophilin a as granulocytopoiesis stimulant, radioprotector and immune stimulant |
| US20090324583A1 (en) * | 2008-06-30 | 2009-12-31 | Ewha University-Industry Collaboration Foundation | Methods for inducing the differentiation of hematopoietic stem cells into megakaryocytes and platelets, and gene controlling the differentiation |
| RU2010105690A (en) * | 2007-07-18 | 2011-08-27 | Лайфскен, Инк. (Us) | HUMAN FEMORATION OF EMBRYONAL STEM CELLS |
-
2012
- 2012-02-27 RU RU2012106870/15A patent/RU2482870C1/en active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990012108A1 (en) * | 1989-04-03 | 1990-10-18 | Genetics Institute, Inc. | Megakaryocyte growth promoting activity |
| US20090226406A1 (en) * | 2002-04-12 | 2009-09-10 | Hariri Robert J | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| WO2007058497A1 (en) * | 2005-11-17 | 2007-05-24 | Ewha University - Industry Collaboration Foundation | Method for inducing the differentiation of human myelogenous leukemia cells into megakaryocytes or thrombocytes |
| RU2010105690A (en) * | 2007-07-18 | 2011-08-27 | Лайфскен, Инк. (Us) | HUMAN FEMORATION OF EMBRYONAL STEM CELLS |
| RU2370277C1 (en) * | 2008-04-21 | 2009-10-20 | Государственное учреждение Российский онкологический научный центр им Н.Н. Блохина РАМН | Cyclophilin a as granulocytopoiesis stimulant, radioprotector and immune stimulant |
| US20090324583A1 (en) * | 2008-06-30 | 2009-12-31 | Ewha University-Industry Collaboration Foundation | Methods for inducing the differentiation of hematopoietic stem cells into megakaryocytes and platelets, and gene controlling the differentiation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2606764C2 (en) * | 2011-05-13 | 2017-01-10 | Университет Токио | Method for producing polyploidized megakaryocyte and platelets |
| RU2756000C2 (en) * | 2015-09-15 | 2021-09-24 | Мегакарион Корпорейшн | Method for the production of platelets by a method for rotational mixing of the culture |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chou et al. | Stromal-derived IL-6 alters the balance of myeloerythroid progenitors during Toxoplasma gondii infection | |
| Megías et al. | Direct Toll-like receptor-mediated stimulation of hematopoietic stem and progenitor cells occurs in vivo and promotes differentiation toward macrophages | |
| Sitnicka et al. | The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells | |
| Machlus et al. | CCL5 derived from platelets increases megakaryocyte proplatelet formation | |
| Ramachandran et al. | Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy | |
| AU644837B2 (en) | Megakaryocyte production | |
| Verbrugge et al. | Differential expression of leukocyte-associated Ig-like receptor-1 during neutrophil differentiation and activation | |
| KR101493474B1 (en) | Methods for increasing and transferring hematopoietic stem cells | |
| ES2771248T3 (en) | Differentiation of ex vivo NK cells from CD34 + hematopoietic cells | |
| Tamura et al. | Accelerated apoptosis of peripheral blood monocytes in Cebpb-deficient mice | |
| RU2482870C1 (en) | Agent inducing hemopoietic stem cell differentiation into thrombocytes | |
| Peng et al. | Distinct roles of Rheb and Raptor in activating mTOR complex 1 for the self-renewal of hematopoietic stem cells | |
| Chen et al. | Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis | |
| Bruno et al. | Different growth factor requirements for the ex vivo amplification of transplantable human cord blood cells in a NOD/SCID mouse model | |
| Antosova et al. | SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity | |
| Garbe et al. | Transforming growth factor‐beta 1 delays formation of granulocyte‐macrophage colony‐forming cells, but spares more primitive progenitors during ex vivo expansion of CD34+ haemopoietic progenitor cells | |
| Ciraci et al. | Adult human circulating CD34− Lin− CD45− CD133− cells can differentiate into hematopoietic and endothelial cells | |
| EP3148574A1 (en) | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus | |
| RU2360965C1 (en) | METHOD OF INCREASING NUMBER OF PATIENT'S HAEMOPOETIC UNDIFFERENTIATED STEM CELLS ex vivo | |
| KR101169835B1 (en) | Methods for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets | |
| Huang et al. | No significant effects of Poly (I: C) on human umbilical cord-derived mesenchymal stem cells in the treatment of B6. MRL-Faslpr mice | |
| KR101997026B1 (en) | Composition for promoting differentiation or proliferation of natural killer cell comprising sesamolin | |
| Zare et al. | Rapamycin inhibits expansion of cord blood derived NK and T cell | |
| Ling et al. | Recombinant human tyrosyl-tRNA synthetase, a novel thrombopoietic agent | |
| Pless et al. | Synergy of growth factors during mobilization of peripheral blood precursor cells with recombinant human Flt3-ligand and granulocyte colony-stimulating factor in rabbits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| QA4A | Patent open for licensing |
Effective date: 20201123 |